US/UK/Canada

Share

Contacts

  • Fredrik Strömholm

    Partner


    Regeringsgatan 48, 111 56 Stockholm
    +46 (0)76-115 10 65
    http://www.impilo.se/en/
    • Pick a time period -
    Tags ( Active)

    Impilo acquires Qufora in partnership with existing shareholders

    September 2nd, 2024 Copenhagen, Denmark.The investment company Impilo is now the majority shareholder in the Danish medtech company Qufora, which produces clinical aids for patients with chronic bowel conditions. This partnership will enable Qufora to accelerate its international expansion.   In just 18 years, Qufora has established itself as a significant international player in the market for innovative aids in gastroenterology and urology. The company, headquartered in Allerød, Denmark, is currently represented in a range of international markets, with a particular focus on the

    Impilo invests in Avia Pharma – a leading OTC and Rx pharmaceutical platform

    STOCKHOLM, Sweden, 2 February 2024 – Impilo has closed its investment in Avia Pharma Holding AB (“Avia” or the “Company”), a Sweden-based OTC and Rx pharmaceutical company with presence in the Nordics and Germany. Continuing on Impilo’s long-term ambitions of building a leading Northern European OTC/Rx platform, and the work through Mallax, Impilo now partners with two of the co-founders and management of Avia. Our ambition is to build a leading Northern European OTC / Rx platform through organic and inorganic growth. Avia was founded in 2016 and focuses on medically positioned products

    Impilo invests in Pelago Bioscience – a fast-growing drug discovery research partner

    STOCKHOLM, Sweden, 16 August 2023 – Impilo invests in Pelago Bioscience AB (“Pelago” or the “Company”) and enters a partnership with the Founders to accelerate platform expansion. Pelago is a fast-growing drug discovery focused contract research organisation (“CRO”) with a service offering centered around its patented CEllular Thermal Shift Assay (CETSA®) technology. CETSA® provides unique value to customers in accelerating drug discovery projects given its ability to quantify how a drug compound binds to its intended target and perturb the biology in whole-cell physiological conditions.

    Impilo acquires VaccinDirekt – the leading Nordic retail vaccination provider

    STOCKHOLM, Sweden, 16 August 2023 – Impilo has acquired VaccinDirekt from SEB Private Equity and partners with the management team to accelerate expansion of the platform. VaccinDirekt is the largest retail vaccination provider in Sweden where it has established itself as the clear market leader, both in terms of market share and customer satisfaction. With roots back to 1972, the Company has been able to successfully lead the fast-growing retail vaccination market and has five folded the clinic network over the past five years, primarily through greenfield expansion. “VaccinDirekt is

    Impilo invests in Decon – a leading mobility player

    June 29, 2023 – Impilo has acquired a majority position in Decon Wheel AB (“Decon”), a developer and producer of high-quality power assist electrical solutions for manual wheelchairs, from its founders, who will continue as minority owners. In parallel with Impilo’s investment into Decon, Decon will acquire its long-term partner, Mobility Products, in the Netherlands. Decon was founded in 1989 in Hyltebruk, Sweden, and employs c. 40 employees with 2022 sales of SEK 124m. Decon develops, assemblies, and distributes high-quality power-assisted electrical solutions for wheelchairs. With a

    Impilo divests leading haemostatic device developer and manufacturer Ferrosan Medical Devices to Danish consortium of long-term investors

    Impilo AB (“Impilo”) and other minority investors, incl. Hans-Christian Bødker Jensen, have signed an agreement to divest the Danish medical devices company Ferrosan Medical Devices Group A/S (“FeMD”) to a consortium of Danish long-term investors consisting of Kirk Kapital, Lundbeckfonden and ATP (the “Consortium”).Impilo invested in FeMD in 2017 and has together with the management team realised the vision of creating a world leading medical devices group with product innovation and improved health outcomes at the core of its business. During Impilo’s ownership, revenues and EBITDA have

    Scantox acquires Timeline Bioresearch and Adlego Biomedical – strengthening its position as the leading Nordic provider of pre-clinical research services

    Scantox A/S (“Scantox” or the “Company”), the leading Nordic GLP-compliant pre-clinical contract research organization (“CRO”), headquartered in Denmark and since 2021 owned by Impilo, is pleased to announce the acquisitions of Swedish Timeline Bioresearch AB in Lund (“Timeline Bioresearch”) and Adlego Biomedical AB in Stockholm (“Adlego Biomedical”).   Timeline Bioresearch and Adlego Biomedical possess leading capabilities in efficacy and explorative research services and bring highly complementary service offerings to Scantox’s stronghold in pharmacology and regulatory toxicology.

    Impilo invests in Lowenco – a pioneer in ultra-low temperature storage solutions

    VAMDRUP, Denmark, February 3rd, 2022 – Impilo, together with SHS, have acquired Lowenco A/S (“Lowenco” or the “Company”) from its founder and owners.Lowenco was founded 2013 in Vamdrup, Denmark, and develops, manufactures, markets, and installs large scale modular and highly energy efficient ultra-low temperature (“ULT”) storage solutions for commercial biopharma, primarily targeting the drug substance market. Following an initial period of product refinement and establishment of go-to-market activities, Lowenco has over the past three years gained significant commercial traction and is

    Impilo has closed its second investment pool

    Impilo AB, the Nordic investment company focused on healthcare investments, has secured new commitments from new and existing investors of SEK 6bn (EUR 590m) and significantly exceeding its target amount. The capital raised enables new platform investments and follow-on investments in existing portfolio companies. In combination with the value of the current portfolio, Impilo’s total assets under management now exceed SEK 10bn (EUR 980m).“The whole Impilo team is humbled and proud to have been entrusted with this capital and is excited to seek further investments in some of the most dynamic

    Mallax acquires Sana Pharma Medical and creates a new Nordic pharmaceutical platform

    Stockholm, 1 July 2021 - Mallax Pharmaceuticals AB (”Mallax”) has acquired Sana Pharma Medical AS (”SPM” or the “Company”) and creates a new Nordic pharmaceutical platform.Founded in Norway in 2014, SPM is a rapidly growing OTC company with full pharmaceutical infrastructure and distribution coverage across the Nordics. The Company enjoys a leading position within the fast-growing sleep and anxiety category, with well-established brands such as Lunixen and Sedix, as well as other products based on the substance melatonin. SPM is a well-resourced platform with c. 15 FTEs, providing broad in-

    Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Arginase 1 Deficiency in Europe and Middle East

    Aeglea receives $21.5 million upfront with up to approximately $130 million in milestone payments and royalties in the mid-twenties. Immedica obtains exclusive commercialization rights in Europe and several Middle Eastern countries.Austin, Texas, and Stockholm, March 22, 2021 - Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, and Immedica Pharma AB (Immedica) today announced the license and supply agreement for pegzilarginase, a novel, recombinant

    Impilo and Anders Larnholt form a partnership to create a new pan-European pharmaceutical platform

    Stockholm, December 15, 2020 - The Nordic investment company Impilo has partnered with Anders Larnholt, a pharma and healthcare executive and entrepreneur, to create a new platform; Mallax Pharmaceuticals AB* (“Mallax”). Mallax was founded in Sweden, with the aim of building a company with established pharmaceuticals and OTC products for customers and patients across Europe.“I’m very pleased to enter into a partnership with Impilo. They have a profound understanding of the healthcare sector and are long term investors. Sustainability, medical need, and profitable growth are cornerstones of

    Impilo launches collaboration with Kenyan non-profit innovators

    The Nordic investment company Impilo partners with Lwala Community Alliance in Kenya to reduce maternal and child mortality in rural areas. Impilo will provide both financial and strategic support to scale their innovative community-based model.”Impilo invests in companies that enable people to enjoy healthier lives now and in the future. Our partnership with Lwala is another way of contributing to that same objective. Together we will help spread Lwala’s proven model to improve health for the poor in Kenya, and actively engage our employees”, says Veronica Byfield Sköld, Partner at Impilo.

    A consortium of investors arranged by Impilo has entered an agreement to acquire Euro Accident Livförsäkring from National General Holdings Corp.

    Euro Accident is a leading Swedish specialist in health-related insurance and employee wellbeing, active primarily within the long-term disability, pension risk and private health insurance. Euro Accident was founded in 1996 and has experienced strong growth over the past 15 years, enabled by high quality products and leading service that aim at keeping their clients as healthy as possible. Today more than half a million people in Sweden are insured through the company.Impilo together with management and a group of other investors have agreed to acquire Euro Accident from the current owners

    Impilo increases its ownership in Humana and becomes the largest shareholder

    The Nordic investment company Impilo increases its shareholding in Swedish care company Humana AB (publ) (”Humana”), through the acquisition of approximately 6 percent of the shares outstanding from Argan Capital. Through this investment, Impilo becomes the largest shareholder in Humana with a total shareholding of 18.5 percent of the shares outstanding.Humana was founded in 2001 and is a leading provider of care services in the Nordic region, currently with c. 15,000 employees and a turnover of SEK 6.7bn. Humana is the market leader within Individual & Family care services as well as

    Impilo becomes second largest shareholder in Humana

    The Swedish investment company Impilo has entered into an agreement to acquire the equivalent of 12.5 percent of the shares in Swedish care company Humana AB (publ) (”Humana”) from Humana’s largest shareholder, Argan Capital. Through this investment, Impilo becomes the second largest shareholder in Humana and intends to contribute actively in the continued development of the company.Humana was founded in 2001 and is a leading provider of care services in the Nordic region, currently with c. 15,000 employees and a turnover of SEK 6.6bn. Humana is the market leader within Individual & Family

    Impilo launches Immedica – a platform for pan-European niche specialty pharma launch, commercialization and distribution services

    Impilo has launched Immedica Pharma – a pan-European specialty pharma commercialization and distribution platform. Immedica’s plan is to quickly establish a fast-growing EUR 100m+ leading pan-European niche specialty pharma portfolio composed of partner products as well as proprietary products rights – and spanning from pre-approval stage through peak sales. This will be achieved through world-class launch, commercialization, and distribution capabilities lead by a management team with a very strong and established track record within niche specialty pharma.Immedica was formed through the

    Impilo invests in Swedish HIV diagnostics company Cavidi

    Impilo has invested in a 29% stake in Cavidi AB, an Uppsala-based diagnostics company focused on HIV Viral Load monitoring. Cavidi has developed a new fully automated viral load diagnostic platform. This platform, Ziva™, aims to meet the need for cost-effective monitoring in high-disease burden countries.“We launched development of the Ziva platform with a loan from the European Investment Bank, our first institutional capital.  We have now largely completed Ziva development and established a distribution agreement with a top 10 global diagnostic company. With this financing, we have

    Impilo adds senior resources

    Impilo, the Nordic investment company focusing on healthcare and health-related investments has recruited two new team members. Impilo now has eight investment professionals and three industrial partners with complementary backgrounds.- Magnus Edlund joins Impilo as an investment partner after nine years at Altor Equity Partners, and prior to that five years at the Boston Consulting Group; Magnus has an MSc. in Industrial Engineering and Management from the Royal Institute of Technology in Stockholm. - Jens Bager joins Impilo as an industrial partner; most recently, Jens was the CEO of

    Impilo acquires Ferrosan Medical Devices, a global leading manufacturer of hemostats

    PRESS RELEASE Copenhagen 2017-07-07 Impilo has acquired 37 percent of the shares in Ferrosan Medical Devices (FeMD) that develops and produces hemostatic products used to stop bleeding during surgery, as well as miniature electrical engineering used in equipment for regional anesthesia and minimal invasive surgery. FeMD has approximately 220 employees and has production sites and offices in Søborg, Denmark, and in Szczecin, Poland. Sellers are a consortium of Nordic investors and the transaction closed at the end of June.FeMD is a company with a strong product, development and

    Healthcare focused investment company Impilo established

    The investment company Impilo has now been established. The Sweden-based company will focus on the pharmaceutical, medical technology and devices, care services and health-related segments, including preventative care. Impilo is led by five partners with nearly 80 years of experience from investments in the Nordic region. Today the company has SEK 3 bn in commitments from Nordic and international investors.“To us, it is a matter of credibility,” says Fredrik Strömholm, founder and partner with a long experience from Altor, Goldman Sachs and Nordic Capital. “We are based where we are active

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media